Cambridge, Massachusetts–based Cognito Therapeutics develops a non-invasive neuromodulation device that delivers proprietary gamma frequency light and sound stimulation. The company’s investigational device is intended to treat Alzheimer’s disease.
Howell joins the company with more than 20 years of medical device experience. His past includes responsibilities in business development, commercial leadership, product management, market development and strategy.
Before joining Cognito, Howell served as SVP and GM of Aetion’s medical device and diagnostic group. Prior to that, Howell had a nearly 15-year stint at Medtronic, leading its value-based healthcare partnerships organization. He also held P&L responsibility for Medtronic’s integrated health solutions program.
“I’m excited to be joining Cognito and for the opportunity to support its mission to advance disease-modifying therapies for patients with neurodegenerative diseases,” Howell said. “I am looking forward to working with the team to build upon our commercial strategy, with the ultimate goal of making a meaningful difference in the lives of patients with neurodegenerative diseases.”
Cognito Therapeutics CEO Brent Vaughan called Howell “an accomplished leader with a strong track record.” He lauded his expertise in building commercial teams and driving commercial launches in the medical device industry.
“Over the last two decades, he has worked closely with public and private payers in the development of innovative reimbursement models, with key relationships with regulators, public and private payer organizations, top healthcare systems, and industry stakeholders,” Vaughan said. “We look forward to Christian joining our executive leadership team, and his invaluable expertise and relationships will play a vital role in commercialization of our lead product in Alzheimer’s and other neurodegenerative disorders.”
